Blind randomised non-crossover long-term trial comparing topical timolol 0.25% with timolol 0.5% in the treatment of simple chronic glaucoma.

AUTOR(ES)

Mills, K. B.

RESUMO

The results of a 12-month blind randomised trial comparing the intraocular pressure lowering effect of timolol 0.25% with timolol 0.5% are presented. 27% of patients (22% of eyes) required additional antiglaucoma medication after a minimum time interval of 6 months to maintain an intraocular pressure less than 23 mmHg. The mean reduction in intraocular pressure (from pretreatment values) at 12 months was 24% for eyes treated with timolol 0.25% and 19% for eyes treated with timolol 0.5%. When reductions in intraocular pressure at each follow-up interval were statistically significant (timolol 0.25% treated eyes compared with timolol 0.5% treated eyes), the significance always favoured timolol 0.25%.

Documentos Relacionados

• A blind randomised cross-over trial comparing metipranolol 0.3% with timolol 0.25% in open-angle glaucoma: a pilot study.
• Topical idoxuridine for treatment of genital warts in males. A double-blind comparative study of 0.25% and 0.5% cream.
• Podophyllin 0.5% or 2.0% v podophyllotoxin 0.5% for the self treatment of penile warts: a double blind randomised study.
• Long-term outcome of primary acute angle-closure glaucoma.
• Long-term follow up of primary trabeculectomy for infantile glaucoma.